- NZ$9.80m
- NZ$9.42m
- NZ$1.51m
Brief: Rua Bioscience CEO Rob Mitchell To Retire
Brief: Rua Bioscience Received Narcotic License For Distribution And Marketing
Brief: Cann Group Says Acquisition Of Zalm Therapeutics By Rua Bioscience Approved By Rua Shareholders
Brief: Rua Bioscience Says Shareholders Approve Zalm Therapeutics Share Issue
NZ's Rua Bioscience acquires rival cannabis co, shares up
Brief: Rua Bioscience Says It Entered Agreement To Acquire Zalm Therapeutics
NZ's Rua Bioscience rises on regulatory nod to produce cannabinoid oil
Brief: Rua Bioscience Posts FY Loss Before Tax Of NZ$6.17 Mln
Brief: Rua Bioscience Says Agreement With Medbloom Ltd Has Been Concluded
Brief: Rua Bioscience Says HY Operating Loss NZ$3.48 Million